Transduction, Tropism, and Biodistribution of AAV Vectors in the Lacrimal Gland

Eduardo M. Rocha,1,2 Giovanni Di Pasquale,1 Paola Perez Riveros,1 Katrina Quinn,1 Beverly Handelman,1 and John A. Chiorini1

PURPOSE. The lacrimal gland (LG) delivers defensive and metabolic factors to the ocular surface. These functions may be disrupted in several diseases, and for most of them there is no cure. The aim of this study is to investigate conditions and limitations for using adeno-associated virus (AAV) vectors as gene transfer agents to LG.

METHODS. Eight-week-old Balb/c mice were used to investigate route, gene expression, and time course of AAV gene vector transfer to LG. AAV vectors encoding firefly luciferase were administered to the LG and luciferase expression was evaluated in vivo by immunohistochemistry. Ocular surface and neutralizing antibodies were also evaluated.

RESULTS. The present work revealed that AAV vectors are able to deliver DNA to the LGs of mice. Direct injection had the highest level of transduction, and topical ocular drops the lowest. Overall, the AAV strain with highest transduction activity as measured by both luminescence and immunohistochemistry was AAV9, followed by AAV 5w8 and AAV5. Transduction was not different between sexes, could be detected as soon as 24 hours after injection, and lasted for at least 30 days (study termination). No tissue damage was observed when compared with controls. All vectors with detectable LG transduction induced neutralizing antibodies.

CONCLUSIONS. LG gene delivery by AAV vectors appears to be both safe and well tolerated. The choice of vector influences both the overall transduction activity, as well as the spread of vector to other organs. This work supports the use of AAV-mediated gene therapy for dry eye. (Invest Ophthalmol Vis Sci. 2011;52:9567-9572) DOI:10.1167/iovs.11-8171

The lacrimal gland (LG) is part of the immune secretory system responsible for maintaining moisture, protection, and secretion of metabolic elements necessary for clear vision and maintenance of the ocular surface.1,2 Sjögren’s Syndrome (SS) and many other diseases cause dryness of the ocular surface as well as other mucosal and skin tissues.3 The tears are complex secretions that wet and protect the cornea and the conjunctiva and are controlled by neural, immune, and endocrine systems inputs. Disruption in one or more of these systems are known to cause LG dysfunction; they induce clinical signs and symptoms of dryness in several organs, and most have no cure.4-6

Considering that LG dysfunction is presently incurable, has several different causes, and the diagnostic tools have low sensitivity and specificity, better understanding of the viral vector gene transfer to this organ may support the development of tools for future diagnostic and therapeutic strategies.

In support of that assumption, previous work has demonstrated gene transfer to the LG using adeno viral vectors (AdV) encoding TNF-α inhibitor, or adeno-associated viral vector (AAV) encoding IL-10 in rabbit LG.7,8 In addition, overexpression of protein kinase C delivered by adeno viral gene transfer to the acinar cells of the rat LG increased basal- and adrenergic-stimulated protein secretion.9 Furthermore, ocular surface treatment with vectors has been recently reported by delivery of alkaline phosphatase to mouse and human corneal stroma by AAV-6, 8, and 9 vectors, between 14 and 30 days, without signs of inflammation.10

The aims of this study are to investigate the safety and efficiency of AAV as a gene transfer vector for potential lacrimal gland therapy, and to establish the best route, AAV serotype, dose, and kinetics in mice LG in preparation for future studies with dry eye disease and SS.

MATERIALS AND METHODS

Eight-week-old male and female mice were obtained from The Jackson Laboratories (Bar Harbor, ME). All experimental studies were performed according to the “Principles of laboratory animal care” (NIH publication no. 85-23) and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and approved by the Animal Care and Use Committee and NIH Biosafety Committee.

Animals had free access to standard rodent chow and water. Anesthesia consisted of a mix of ketamine (KetaVed Vedco Inc., St. Joseph, MO) (100 mg/mL), 1 mL/kg of body weight; and xylazine (Lloyd Inc., Shenandoah, IA) (20 mg/mL), 0.7 mL/kg body weight; was administered intramuscularly before surgical procedure, and later before tissue collection. In vivo luminescence expression and tear film measurements were conducted under mild anesthesia with 3% isoflurane (Florane; Baxter, Deerfield, IL), together with O3 in a vaporizer (Impac 6, VetEquip Inc., Pleasanton, CA). All procedures and manipulation were conducted just after confirming abolition of the caudal and corneal reflex.
Vector Preparation

Generation of recombinant AAV vectors was performed as previously described. Briefly, 293T cells were cotransfected by calcium phosphate precipitation with the following transplasmids: pMMTV2.1 (provides the AAV serotype 2 Rep); the AAV Cap genes corresponding to the strains studied here; pAd12 (provides adenoviral helper genes); and a vector plasmid, containing luciferase cDNA with a cytomegalovirus (CMV) promoter flanked by the AAV 2, inverted terminal repeats. The cells were harvested 48 hours posttransfection and a crude viral lysate was obtained after three freeze-thaw cycles. The lysate was treated with benzonate, adjusted to a refractive index of 1.372 by addition of CsCl, and centrifuged at 38,000g for 65 hours at 20°C (Sorvall Discovery 100 SE, Kendro Laboratory Products, Newtown, CT). Equilibrium density gradients were fractionated, and fractions with a refractive index of 1.369 to 1.375 were collected and stored at 4°C before assay for transduction activity. Immediately before use, vector fractions were dialyzed against 0.9% NaCl. The number of AAV genomes (particles) was estimated using a qPCR assay, amplifying a CMV promoter region of the vector genome using an automated sequence detector (ABI Prism 7700 Sequence Detector; Applied Biosystems, Carlsbad, CA). Vector titers and concentrations were adjusted based on the qPCR assay to achieve values of 5 x 10^12 particles/mL.

Animal Procedure and Evaluation

Before gene vector studies, trypan blue (TB) (Lonza, Walkensville, MD) at a dilution of 0.04% staining assays were conducted to investigate the reproducibility of drug delivery by different approaches and solution volumes. The mouse extra orbital LG was injected with TB via each specified in the text, directly injected in the exposed LG, or instilled overnight. The next day, 50 μL of firefly luciferin per well (Bright-Glo; Promega, Madison, WI), or otherwise negative control. Afterward, the solution was removed and the cells incubated for 1 hour at 37°C. Serum from naïve animals was used as a negative control. After the solution was removed and the cells incubated for 3 days with DMEM containing 1% fetal calf serum, 1% antibiotic/antimycotic solution and 1% l-glutamine (Gibco; Invitrogen Co.). Measurement of luciferase transduction was performed by adding 20 μL of firefly luciferin per well (Bright-Glo; Promega, Madison, WI), and relative light units detected in each well by a luminometer (Op-tocomp I; MGM Instruments Inc., Hamden, CT). Results were expressed as the neutralization titer that inhibited 50% of transduction with AAV vector, compared with serum from naïve animals. Therefore the lower the titer, the fewer antibodies are present. All samples were assayed in triplicate.

AAV Neutralizing Antibody Assay

Cos-7 cells were seeded at 7 x 10^5 cells per well of a 96-well plate overnight. The next day, 50 μL of serum (previously diluted, twofold from 1:25 to 1:1600 in 1% horse serum DMEM) from mice injected in the LG with one of the following viruses: AAV2, 4, 5, x5, 5 w8, 9, 12, and BAAV containing luciferase gene was pre-incubated with an equal volume of their respective virus particles for 1 hour at room temperature. Serum/vector mixture was added in triplicate to Cos-7 cells and incubated for 1 hour at 37°C. Serum from naïve animals was used as a negative control. Afterward, the solution was removed and the cells incubated for 3 days with DMEM containing 1% fetal calf serum, 1% antibiotic/antimycotic solution and 1% l-glutamine (Gibco; Invitrogen Co.). Measurement of luciferase transduction was performed by adding 20 μL of firefly luciferin per well (Bright-Glo; Promega, Madison, WI), and relative light units detected in each well by a luminometer (Op-toomp I; MGM Instruments Inc., Hamden, CT). Results were expressed as the neutralization titer that inhibited 50% of transduction with AAV vector, compared with serum from naïve animals. Therefore the lower the titer, the fewer antibodies are present. All samples were assayed in triplicate.

Statistical Analysis

Data, unless otherwise indicated, were expressed as mean ± SD. Comparisons were made using the Kruskal-Wallis test for continuous data comparison among several groups and the Mann-Whitney U test for continuous data comparison between males and females (Graphpad 5.0 software; Prism, San Diego, CA). The level of significance used was P < 0.05.
RESULTS

Delivery Route for LG Medication

Mice LG duct cannulation as has been reported for the salivary gland followed by trypan blue (TB) staining failed to stain the LG (data not shown). Puncture injection through the skin left TB in the subcutaneous space. The most successful route of application of recombinant (r)AAV-Luc was by injection of the LG after surgical opening of skin and LG exposure. This method allowed good distribution of TB in the target tissue. In addition, topical ocular application was conducted with the findings described below.

In Vivo Imaging Detects Serotype-Dependent Transgene Expression Assay and Biodistribution

Twenty-four hours, and 7, 14, and 30 days after injection, expression of luciferase was measured by luminescence imaging. AAV9, followed by AAV 5w8 and AAV5 demonstrated the fastest and most intense transduction. AAV9 and AAV2 showed a continuous increase in luciferase expression over the 30-day period of study and at Day 30 AAV2 showed levels of expression similar to AAV 5. In contrast, AAV 5w8 showed stable expression, initially starting at Day 7 and continuing until the end of the study (30 days) (Figs. 1, 2A).

In addition to expression at the site of injection, luminescence imaging detected AAV9 and AAV12 transduction at distal sites, more specifically in the abdominal area, right subcostal region for AAV9 (Fig. 2B) and inferior central area of the abdomen for AAV12 (data not shown). Quantification of luminescence in the abdominal area revealed high levels of AAV9 expression (Fig. 2E). In contrast AAV5 and AAV 5w8 transduction appeared to stay more localized to the LG, however some expression was still detected after removal of the gland suggesting some spreading to the adjacent tissues (Fig. 2C). More extensive spreading was detected if the AAV 5 vector dose was increased fivefold, including in the abdomen (i.e., from $1 \times 10^{10}$ to $5 \times 10^{10}$ particles) (data not shown).

Previous studies revealed striking sex-related differences in the LG. In addition, gene transfer studies with AAV2 into mouse submandibular salivary glands have suggested that transduction activity can be significantly (260-fold) lower in female mice. However in LG no sex bias in transduction activity was detected at 7, 14, and 30 days using AAV 5w8 vector (Fig. 3).

To test for transduction after topical application of AAV vectors, $2 \times 10^{12}$ particles per mL were applied to the ocular surface and then mice were prevented from blinking or moving for 2 minutes. Mild luminescence was observed in the first 24 hours, with AAV9 only (Fig. 2D). However, this corneal or regional luminescence was not seen in subsequent evaluations at Day 5 and Day 30 for all virus serotypes (data not shown).

Serotype-Dependent Immunohistochemical Staining of Lacrimal Ductal and Acinar Cells

Immunoperoxidase staining was used to confirm AAV transduction and to locate positive cells within the gland. AAV4 and BAAV showed no staining in the LG, confirming the lack of transduction seen with luciferase imaging. AAV9, AAV5w8, and AAV5 revealed intense staining in acinar cells. AAV5 showed some positive acinar cells. On the other hand, AAV2 primarily transduced ductal epithelial cells whereas AAV12 showed mild but mixed transduction in both acinar and ductal cells (Fig. 4A–I).
Neutralizing Antibody Formation after Lacrimal Gland Transduction

To investigate whether delivery of AAV vectors to the LG induced an immune response, neutralizing antibody assays were performed. The assay showed that animals injected with AAV5, AAV5w8, AAV9, AAV12, and BAAV produce a significant amount of neutralizing antibodies compared with serum from mice injected with AAV2, AAV4, AAVx5, and BAAV which generated a lower neutralizing response (Table 1).

AAV Gene Transfer to the Lacrimal Gland Is Well Tolerated

To test whether AAV either injected into the LG or applied topically, would disrupt the homeostasis between the LG and ocular surface, the eyes of mice were examined directly and by histologic analysis. The direct observation of the eyes did not show signs of inflammation, neovascularization, epithelial defect, corneal edema or opacity, regardless of whether AAV suspension was injected into their LG or topically applied to the ocular surface (Fig. 5C). Tear secretion measurement did not show differences between transduced and naïve animals. Similarities were also seen in the body and LG weight of these animals compared with controls (Table 2). Slides stained with H&E revealed that neither LG nor ocular surface structures were altered by the presence of AAV vectors of all serotypes. There was no inflammatory infiltrate and the architecture of acinar or ductal epithelial cells did not change. In addition, the corneal epithelium was intact, with all epithelial layers pre-

![Image of AAV 5w8 in LG](https://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933457/)
served and no inflammatory cells present in the corneal stroma or conjunctival tissue (Figs. 5A, 5B).

**DISCUSSION**

The present work describes the activity, biodistribution, and host response to eight serotypes of adeno-associated viral vectors on injection into the LG gland of mice. Current treatment for dry eye symptoms related to Sjögren’s syndrome or other causes is typically delivered as a topical therapy, yet recent studies have revealed that the actual therapeutic benefit of this method of treatment is modest according to clinical and patient perspectives. Viral gene therapy to induce production of proteins locally in the LG represents an alternative approach. This finding is in agreement with previous studies that have a larger tear volume, transduction of LG resulted in normal strain) it can be difficult to measure recombinant protein production. Although not tested in this study, proteins should be able to be secreted into the tears from the transduced LG tissue. In two previous studies using rabbit models, which have a larger tear volume, transduction of LG resulted in detection of the recombinant protein (i.e., TNF-α soluble receptor and IL-10) in the tears. The efficiency of transduction is determined by several factors including mechanical barriers, innate and immune defense, concentration of virus suspension, cell affinity to the different viral capsids, and the capacity of the cell to express the encoded gene. Among the 100 AAV isolates reported, less than 10 were tested in exocrine gland or ocular tissue. As observed here, by in vivo luminescence assays, the transduction of LG was more efficient with AAV9 encoding luciferase. A similar effect was obtained in the corneal stroma of mice, when AAV 9 was compared with rAAV8 and 6 encoding alkaline phosphatase.

Another relevant aspect related to the development of a vector for gene transfer is the host immune response to the vector. The mice in our study maintained body weight and had no inflammation or impaired function of the LG, or change in ocular surface with all AAV tested, which suggests that this is a safe strategy for potential use in LG disease treatment. In contrast, one aspect that needs further consideration is the spread of AAV observed with high doses of AAV5, as well as lower doses of AAV9 and AAV12 and their tropism for organs in the abdominal area. It was observed before that adenovirus administered to rat salivary gland has dose-dependent capacity to spread to the abdominal area, heart, and central nervous system. In addition, after retrodudal injection into salivary gland of mice, AAV2, revealed higher capacity to spread compared with AAV4 and 5.

Ideally, a therapeutic viral vector should be able to be readministered if necessary (e.g., expression decrease over time). However, the present work indicates that in LGs, AAV vectors that lead to higher transduction tend to induce higher levels of neutralization antibodies and are therefore likely to have reduced performance in repeat administrations. Considering the present findings, this work suggests that AAV5, or its related mutant AAV5 w8 may be better suited for

**TABLE 2.** Comparison among Body Weight, LG Weight, and Tear Secretion Measurement with Phenol Red Thread in Naïve Controls and Mice Injected with AAV in the LG

<table>
<thead>
<tr>
<th>AAV</th>
<th>Body Weight (g)</th>
<th>LG Weight (mg)</th>
<th>Phenol Red Thread (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>rAAV 2 (n = 3)</td>
<td>29.7 ± 0.6</td>
<td>17.0 ± 2.4</td>
<td>5.5 ± 1.1</td>
</tr>
<tr>
<td>rAAV 4 (n = 2)</td>
<td>29.5 ± 1.3</td>
<td>16.3 ± 3.6</td>
<td>6.0 ± 1.8</td>
</tr>
<tr>
<td>rAAV 5 (n = 3)</td>
<td>28.8 ± 1.3</td>
<td>N/M</td>
<td>5 ± 0.5</td>
</tr>
<tr>
<td>rAAV 5w8 (n = 2)</td>
<td>29.3 ± 1.7</td>
<td>N/M</td>
<td>5.8 ± 0.5</td>
</tr>
<tr>
<td>rAAV 8 (n = 3)</td>
<td>28.1 ± 2.7</td>
<td>19.6 ± 2.5</td>
<td>6.5 ± 1.8</td>
</tr>
<tr>
<td>rAAV 9 (n = 2)</td>
<td>28.1 ± 0.1</td>
<td>N/M</td>
<td>6.0 ± 1.6</td>
</tr>
<tr>
<td>rAAV 12 (n = 2)</td>
<td>28.9 ± 0.6</td>
<td>N/M</td>
<td>6.0 ± 0.8</td>
</tr>
<tr>
<td>rBAAV (n = 3)</td>
<td>30.8 ± 0.4</td>
<td>24.8 ± 2.1</td>
<td>6.5 ± 0.6</td>
</tr>
<tr>
<td>Control (n = 3)</td>
<td>29.8 ± 1.8</td>
<td>21.5 ± 2.1</td>
<td>6.3 ± 1.6</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD. N/M, not measured.
LG gene therapy. However, other serotypes also demonstrate transduction activity in the lacrimal gland. Previous studies observed transient improvement in function and inflammation in a rabbit model of autoimmunity with TNF-alpha inhibitor or IL-10 expressed from adenovirus vector and longer benefits when IL-10 was expressed from AAV2 vector.7,8,26

In conclusion, the present work demonstrates for the first time the feasibility of gene transfer to the LG in mice and the systemic repercussions, to the vector as well as spread to other organs. Use of these vectors should enhance our understanding of lacrimal gland biology and the development of new therapies for the treatment of ocular dryness and lacrimal gland dysfunction.

Acknowledgments

The authors thank William Swaim, Hongen Yin, Ana Paola Cotrim, Milton Papa, and Ilias Alevizos from NIDCR/NIH and Driss Zoukhri from Tufts University School of Dental Medicine for assistance with this work.

References